A phase II randomised controlled trial of adjuvant tumour-infiltrating lymphocytes for pretreatment Epstein-Barr virus DNA-selected high-risk nasopharyngeal carcinoma patients
Yu-Jing Liang, Qiuyan Chen, Jing-xiao Xu, Xiufeng Liu, Jian‐Chuan Xia, Li‐Ting Liu, Shanshan Guo, Bin Song, Pan Wang, Jibin Li, Qing Liu, Hao‐Yuan Mo, Ling Guo, Rui Sun, Dong–Hua Luo, Jia He, Yina Liu, Cai-Ping Nie, Lin‐Quan Tang, Jiang Li, Hai‐Qiang Mai
Topics & Concepts
MedicineNasopharyngeal carcinomaInternal medicineTumor-infiltrating lymphocytesAdverse effectHazard ratioOncologyAdjuvantCD8Clinical endpointConfidence intervalGastroenterologyClinical trialImmunologyImmunotherapyImmune systemRadiation therapyCancerCancer Immunotherapy and BiomarkersViral-associated cancers and disordersHead and Neck Cancer Studies